CNBX Pharmaceuticals Inc. (CNBX)
- Previous Close
0.0130 - Open
0.0122 - Bid --
- Ask --
- Day's Range
0.0107 - 0.0125 - 52 Week Range
0.0100 - 0.0500 - Volume
1,210,144 - Avg. Volume
244,842 - Market Cap (intraday)
336,003 - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
0.01 - EPS (TTM)
0.9800 - Earnings Date Jul 14, 2024 - Jul 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.
www.cnbxpharma.comRelated News
Performance Overview: CNBX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNBX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNBX
Valuation Measures
Market Cap
336.00k
Enterprise Value
1.59M
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.45
Price/Book (mrq)
--
Enterprise Value/Revenue
2.95
Enterprise Value/EBITDA
-0.48
Financial Highlights
Profitability and Income Statement
Profit Margin
-228.09%
Return on Assets (ttm)
-142.36%
Return on Equity (ttm)
--
Revenue (ttm)
540.24k
Net Income Avi to Common (ttm)
-1.23M
Diluted EPS (ttm)
0.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
37.14k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
65.66k
Company Insights: CNBX
CNBX does not have Company Insights